Fenwick Represents Axiom in $15M Series Seed Funding

Fenwick represented Axiom, a biotech company building AI models to predict the toxicity of drug candidates, in its $15 million Series Seed funding. The round included participation from Amplify Partners, Dimension Capital, and Zetta Venture Partners.

Axiom will use the funds to continue to focus on predicting liver toxicity. More information can be obtained here.

The Fenwick transaction team was led by corporate partners Michael Brown and Chance Goldberg and included associates Joon Kim, Teresa Anselmo-Thai and Bradley Shepard.